FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103184621> ?p ?o ?g. }

• W2103184621 endingPage "1403" @default.
• W2103184621 startingPage "1394" @default.
• W2103184621 abstract "Human MYCN (hMYCN) oncogene amplification is a powerful predictor of treatment failure in childhood neuroblastoma, and dysregulation of hMYCN protein expression appears to be critically involved in the pathogenesis of this disease. We used hMYCN antisense (AS) oligonucleotides to investigate, both in vitro and in vivo, the therapeutic potential of inhibiting hMYCN expression.We transiently transfected human neuroblastoma IMR-32 cells, which have an amplified hMYCN gene, with fluorescently labeled hMYCN AS or scrambled (SCR) control oligonucleotides and used fluorescence-activated cell sorting to enrich for cell populations containing different levels of the oligonucleotides. We used fluorescence immunocytochemistry or reverse transcription polymerase chain reaction to assay gene expression levels and trypan blue exclusion to assay growth inhibition in the cell populations. We examined the effects of continuous treatment for 6 weeks with AS or SCR oligonucleotides via subcutaneously implanted microosmotic pumps on tumor growth in a transgenic mouse model of hMYCN-induced neuroblastoma (n = 20 mice per group). All statistical tests were two-sided.IMR-32 cells treated with AS oligonucleotides had approximately half as much hMYCN protein and cell proliferation as either SCR oligonucleotide-transfected or mock-transfected controls; the differences were statistically significant. Transgenic mice treated with AS oligonucleotides had lower tumor incidence and statistically significantly lower tumor mass than SCR-treated or untreated control mice. Compared with control treatments, AS oligonucleotide treatment in vitro and in vivo was associated with decreased expression of hMYCN and putative hMYCN target genes but not with that of closely related genes. Several AS oligonucleotide-treated mice developed tumors contralateral to the site of oligonucleotide administration, whereas SCR oligonucleotide-treated or untreated mice displayed bilateral tumor growth.Decreased expression of hMYCN protein is achievable with the use of AS oligonucleotide treatment, even in the presence of hMYCN oncogene amplification. Antisense strategies targeting the hMYCN oncogene in vivo decrease mouse neuroblastoma tumorigenesis. Investigation of their clinical effect in children with neuroblastoma is warranted." @default.
• W2103184621 created "2016-06-24" @default.
• W2103184621 creator A5011765291 @default.
• W2103184621 creator A5015754037 @default.
• W2103184621 creator A5019424502 @default.
• W2103184621 creator A5026784302 @default.
• W2103184621 creator A5032972462 @default.
• W2103184621 creator A5041227247 @default.
• W2103184621 creator A5065860849 @default.
• W2103184621 creator A5072009574 @default.
• W2103184621 creator A5078090612 @default.
• W2103184621 creator A5083210836 @default.
• W2103184621 date "2003-09-16" @default.
• W2103184621 modified "2023-09-23" @default.
• W2103184621 title "Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma" @default.
• W2103184621 cites W1583339960 @default.
• W2103184621 cites W173611128 @default.
• W2103184621 cites W1983241347 @default.
• W2103184621 cites W1984529434 @default.
• W2103184621 cites W1988506250 @default.
• W2103184621 cites W1995996044 @default.
• W2103184621 cites W1996949194 @default.
• W2103184621 cites W2000931945 @default.
• W2103184621 cites W2016620103 @default.
• W2103184621 cites W2024280594 @default.
• W2103184621 cites W2024412859 @default.
• W2103184621 cites W2037213956 @default.
• W2103184621 cites W2044033792 @default.
• W2103184621 cites W2044261735 @default.
• W2103184621 cites W2059433877 @default.
• W2103184621 cites W2063647772 @default.
• W2103184621 cites W2066412555 @default.
• W2103184621 cites W2067339749 @default.
• W2103184621 cites W2089267579 @default.
• W2103184621 cites W2113211717 @default.
• W2103184621 cites W2115987795 @default.
• W2103184621 cites W2125089526 @default.
• W2103184621 cites W2151547689 @default.
• W2103184621 cites W2183635321 @default.
• W2103184621 cites W2229138924 @default.
• W2103184621 cites W2244299590 @default.
• W2103184621 cites W2245205914 @default.
• W2103184621 cites W2248643920 @default.
• W2103184621 cites W2290539832 @default.
• W2103184621 cites W2320504400 @default.
• W2103184621 cites W2329408473 @default.
• W2103184621 cites W2330923897 @default.
• W2103184621 cites W4361851957 @default.
• W2103184621 cites W62587231 @default.
• W2103184621 doi "https://doi.org/10.1093/jnci/djg045" @default.
• W2103184621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/13130115" @default.
• W2103184621 hasPublicationYear "2003" @default.
• W2103184621 type Work @default.
• W2103184621 sameAs 2103184621 @default.
• W2103184621 citedByCount "89" @default.
• W2103184621 countsByYear W21031846212012 @default.
• W2103184621 countsByYear W21031846212013 @default.
• W2103184621 countsByYear W21031846212014 @default.
• W2103184621 countsByYear W21031846212015 @default.
• W2103184621 countsByYear W21031846212016 @default.
• W2103184621 countsByYear W21031846212017 @default.
• W2103184621 countsByYear W21031846212018 @default.
• W2103184621 countsByYear W21031846212019 @default.
• W2103184621 countsByYear W21031846212020 @default.
• W2103184621 countsByYear W21031846212021 @default.
• W2103184621 countsByYear W21031846212022 @default.
• W2103184621 countsByYear W21031846212023 @default.
• W2103184621 crossrefType "journal-article" @default.
• W2103184621 hasAuthorship W2103184621A5011765291 @default.
• W2103184621 hasAuthorship W2103184621A5015754037 @default.
• W2103184621 hasAuthorship W2103184621A5019424502 @default.
• W2103184621 hasAuthorship W2103184621A5026784302 @default.
• W2103184621 hasAuthorship W2103184621A5032972462 @default.
• W2103184621 hasAuthorship W2103184621A5041227247 @default.
• W2103184621 hasAuthorship W2103184621A5065860849 @default.
• W2103184621 hasAuthorship W2103184621A5072009574 @default.
• W2103184621 hasAuthorship W2103184621A5078090612 @default.
• W2103184621 hasAuthorship W2103184621A5083210836 @default.
• W2103184621 hasBestOaLocation W21031846211 @default.
• W2103184621 hasConcept C102230213 @default.
• W2103184621 hasConcept C104317684 @default.
• W2103184621 hasConcept C129312508 @default.
• W2103184621 hasConcept C141035611 @default.
• W2103184621 hasConcept C1491633281 @default.
• W2103184621 hasConcept C150194340 @default.
• W2103184621 hasConcept C150903083 @default.
• W2103184621 hasConcept C153911025 @default.
• W2103184621 hasConcept C207001950 @default.
• W2103184621 hasConcept C2776715637 @default.
• W2103184621 hasConcept C2778630268 @default.
• W2103184621 hasConcept C2781018059 @default.
• W2103184621 hasConcept C29537977 @default.
• W2103184621 hasConcept C502942594 @default.
• W2103184621 hasConcept C54009773 @default.
• W2103184621 hasConcept C54355233 @default.
• W2103184621 hasConcept C553184892 @default.
• W2103184621 hasConcept C55493867 @default.
• W2103184621 hasConcept C555283112 @default.

• next